Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme

E-ISSN： 2212-3938|11|4|259-264

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.11, Iss.4, 2016-12, pp. : 259-264

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Methylmercury-Induced Inhibition of Paraoxonase-1 (PON1)—Implications for Cardiovascular Risk

Journal of Toxicology and Environmental Health, Vol. 77, Iss. 17, 2014-09 ,pp. : 1004-1023

Taylor & Francis Ltd

Access to resources Recommend Favorite

Genetic Polymorphism in Paraoxonase 1 (PON1): Population Distribution of PON1 Activity

By Ginsberg Gary

Journal of Toxicology and Environmental Health Part B: Critical Reviews, Vol. 12, Iss. 5-6, 2009-05 ,pp. : 473-507

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 8, 2009-07 ,pp. : 911-920

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosinase Enzyme: 1. An Overview on a Pharmacological Target

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 12, 2014-06 ,pp. : 1494-1501

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting paraoxonase-1 in atherosclerosis

By Mackness Mike Mackness Bharti

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 7, 2013-10 ,pp. : 829-837

Informa Healthcare

Access to resources Recommend Favorite